Telavancin: A Novel Semisynthetic Lipoglycopeptide Agent to Counter the Challenge of Resistant Gram-Positive Pathogens
Therapeutic Advances in Infectious Disease
doi 10.1177/2049936117690501
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2017
Authors
Publisher
SAGE Publications